Please login to the form below

Not currently logged in
Email:
Password:

U3 Pharma

This page shows the latest U3 Pharma news and features for those working in and with pharma, biotech and healthcare.

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer

The two-stage trial of patritumab (U3-1287/AMG 888) in combination with Roche's EGFR inhibitor Tarceva (erlotinib) patients with non-small cell lung cancer (NSCLC) was stopped on the ... The antibody was developed by Daiichi Sankyo's German subsidiary U3

Latest news

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    Will transfer its operations to a research unit in Japan.  . Daiichi Sankyo has said it will close down its German antibody subsidiary U3 Pharma and transfer its operations to a research ... Martinsried-based U3 Pharma - which was acquired by Daiichi

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics